State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors

Cites (227)

Items 201–227 of 227

1. Immunosuppressive Small Molecule Discovered by Structure‐Based Virtual Screening for Inhibitors of Protein–Protein Interactions
   Tim Geppert, Stefanie Bauer, Jan A. Hiss, Elea Conrad, Michael Reutlinger, Petra Schneider, Martin Weisel, Bernhard Pfeiffer, Karl‐Heinz Altmann, Zoe Waibler et al. · 2011 · Angewandte Chemie International Edition
2. Application of a novel in silico high-throughput screen to identify selective inhibitors for protein–protein interactions
   Catherine Joce, Joshua A. Stahl, Mitesh Shridhar, Mark Rowland Hutchinson, Linda R. Watkins, Peter O. Fedichev, Hang Hubert Yin · 2010 · Bioorganic & Medicinal Chemistry Letters
3. Structural Properties of Non-Traditional Drug Targets Present New Challenges for Virtual Screening
   Ragul Gowthaman, Eric J. Deeds, John Karanicolas · 2013 · Journal of Chemical Information and Modeling
4. Discovery of Low‐Molecular‐Weight Ligands for the AF6 PDZ Domain
   Mangesh Joshi, Carolyn Vargas, Prisca Boisguérin, Anne Diehl, Gerd Krause, Peter Schmieder, Karin Moelling, Volker Hagen, Markus Schade, Hartmut Oschkinat · 2006 · Angewandte Chemie International Edition
5. Thienoquinolines as Novel Disruptors of the PKCε/RACK2 Protein–Protein Interaction
   Florian Rechfeld, Peter Gruber, Johannes Kirchmair, Markus Boehler, N. Hauser, Georg Hechenberger, Dorota Garczarczyk, Gennady B. Lapa, MARIA N. PREOBRAZHENSKAYA, Peter G. Goekjian et al. · 2014 · Journal of Medicinal Chemistry
6. Inhibition of CDC25B Phosphatase Through Disruption of Protein–Protein Interaction
   George Lund, Sergii Dudkin, Dmitry Borkin, Wendi Ni, Jolanta E. Grembecka, Tomasz Cierpicki · 2014 · ACS Chemical Biology
7. Discovery of a Novel Small Molecule Inhibitor Targeting the Frataxin/Ubiquitin Interaction via Structure-Based Virtual Screening and Bioassays
   Antonio Lavecchia, Carmen Di Giovanni, Carmen Cerchia, Annapina Russo, Giulia Russo, Ettore Novellino · 2013 · Journal of Medicinal Chemistry
8. Evaluation of “Credit Card” Libraries for Inhibition of HIV-1 gp41 Fusogenic Core Formation
   Yang Y. Xu, Hong Lü, Jack P. Kennedy, Xuxia Yan, Laura A. McAllister, Noboru Yamamoto, Jason A. Moss, Grant E. Boldt, Shibo Jiang, Kim D. Janda · 2006 · Journal of Combinatorial Chemistry
9. Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library
   Landon R. Whitby, Kristopher E. Boyle, Lifeng Cai, Xiaoqian Yu, Miriam Gochin, Dale L. Boger · 2012 · Bioorganic & Medicinal Chemistry Letters
10. Selectivity by Small-Molecule Inhibitors of Protein Interactions Can Be Driven by Protein Surface Fluctuations
    David K. Johnson, John Karanicolas · 2015 · PLoS Computational Biology
11. Screening Multicomponent Reactions for X-Linked Inhibitor of Apoptosis-Baculoviral Inhibitor of Apoptosis Protein Repeats Domain Binder
    Ilaria Monfardini, Jui‐Wen Huang, Barbara Beck, Jason F. Cellitti, Maurizio Pellecchia, Alexander S. S. Dömling · 2011 · Journal of Medicinal Chemistry
12. Using Fragment-Based Technologies to Target Protein-Protein Interactions
    Justin F. Bower, Andrew Pannifer · 2012 · Current Pharmaceutical Design
13. High-Throughput Selectivity Assays for Small-Molecule Inhibitors of β-Catenin/T-Cell Factor Protein–Protein Interactions
    Min Zhang, Jonathan Leon Catrow, Haitao Ji · 2013 · ACS Medicinal Chemistry Letters
14. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1–E2 protein–protein interaction: A combined medicinal chemistry, NMR and computational chemistry approach
    Nathalie Goudreau, Dale R. Cameron, Robert Déziel, Bruno Haché, Araz Jakalian, Éric Malenfant, Julie Naud, William W. Ogilvie, Jeff A. O’Meara, Peter W. White et al. · 2007 · Bioorganic & Medicinal Chemistry
15. Minimal ensembles of side chain conformers for modeling protein–protein interactions
    Dmitri Beglov, David R. Hall, Ryan Brenke, Maxim V. Shapovalov, Roland L. Dunbrack, Dima Kozakov, Sándor Vajda · 2011 · Proteins Structure Function and Bioinformatics
16. A Mammalian Genetic System To Screen for Small Molecules Capable of Disrupting Protein−Protein Interactions
    Huifen Zhao, Taira Kiyota, Shafinaz F. Chowdhury, Enrico O. Purisima, Denis Banville, Yasuo Konishi, Shi‐Hsiang Shen · 2004 · Analytical Chemistry
17. Fragmenting the S100B–p53 Interaction: Combined Virtual/Biophysical Screening Approaches to Identify Ligands
    Mariangela Agamennone, Lucia Cesari, Daniela Lalli, Elisa Turlizzi, Rebecca Del Conte, Paola Turano, Stefano Mangani, Alessandro Padova · 2010 · ChemMedChem
18. Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists
    Min Zhong, Emily J. Hanan, Shen Wang, Minna Bui, Michelle R. Arkin, Kenneth J. Barr, Marc J. Evanchik, Ute Hoch, Jennifer Hyde, Jose R. Martell et al. · 2010 · Bioorganic & Medicinal Chemistry Letters
19. Fragment-Based Library Generation for the Discovery of a Peptidomimetic p53-Mdm4 Inhibitor
    André Boltjes, Yijun Huang, Rob van de Velde, Laurie K. Rijkee, Siglinde Wolf, James A. Gaugler, Katarzyna Leśniak, Katarzyna Guzik, Tad A. Holak, Alexander S. S. Dömling · 2014 · ACS Combinatorial Science
20. Fragment-Based Identification of a Locus in the Sec7 Domain of Arno for the Design of Protein–Protein Interaction Inhibitors
    Jad Rouhana, François Hoh, Sébastien Estaran, Corinne Henriquet, Yvan Boublik, Aziz Kerkour, Romain Trouillard, Jean Martínez, Martine Pugnière, André Padilla et al. · 2013 · Journal of Medicinal Chemistry
21. Virtual screening for compounds that mimic protein–protein interface epitopes
    Tim Geppert, Felix Reisen, Max Pillong, Volker D. Hähnke, Yusuf Tanrikulu, Christian P. Koch, Anna Maria Perna, Tatiana Batista Perez, Petra Schneider, Gisbert Schneider · 2011 · Journal of Computational Chemistry
22. Non-Peptidic α-Helical Mimetics as Protein-Protein Interaction Inhibitors
    Mahender B. Dewal, Steven M. Firestine · 2011 · Current Medicinal Chemistry
23. A novel drug discovery strategy: Mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways
    Chunlin Zhuang, Chunquan Sheng, Woo Shik Shin, Yuelin Wu, Jin Li, Jianzhong Yao, Guoqiang Dong, Wen Zhang, Yuk Yin Sham, Zhenyuan Miao et al. · 2014 · Oncotarget
24. Facile Synthesis of Pyridazine-Based a-Helix Mimetics
    JULIUS JUN. REBEK, Lionel Moisan, Trevor J. Dale, Naran Gombosuren, Shannon M. Biros, Enrique Mann, Jun‐Li Hou, Fernando R. Pinacho Crisóstomo · 2007 · Heterocycles
25. An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF–GPIbα interaction
    Rani Alphonsa Jose, Arnout R. D. Voet, Katleen Broos, Arjen J. Jakobi, Gilles Bruylants, Brecht Egle, Kam Y. J. Zhang, Marc De Maeyer, Hans Deckmyn, Wim M. De Borggraeve · 2012 · Chemical Communications
26. Antagonists of Protein–Protein Interactions Made Easy?
    Maurizio Pellecchia · 2012 · Journal of Medicinal Chemistry
27. Fragment-based drug discovery: what really works. An interview with Sandy Farmer of Boehringer Ingelheim
    Wendy A. Warr · 2011 · Journal of Computer-Aided Molecular Design